Bioequivalence Study of Klaribact (Clarithromycin) 500 mg, Film Coated Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 23, 2012

Primary Completion Date

November 2, 2012

Study Completion Date

December 25, 2012

Conditions
Healthy VolunteersBioequivalence Study
Interventions
DRUG

Klaribact 500 mg Clarithromycin Tablet

A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.

DRUG

Klaricid 500 mg Clarithromycin Tablet

A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.

Trial Locations (1)

75270

Center for Bioequivalence Studies and clinical research (CBSCR), ICCBS, Karachi

All Listed Sponsors
collaborator

Merck Pvt. Ltd, Pakistan

UNKNOWN

collaborator

Center for Bioequivalence Studies and Clinical Research

OTHER

lead

University of Karachi

OTHER

NCT05436769 - Bioequivalence Study of Klaribact (Clarithromycin) 500 mg, Film Coated Tablet | Biotech Hunter | Biotech Hunter